These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 20515577

  • 1. Incidental non-secreting adrenal masses in cancer patients: intra-individual comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography with computed tomography and shift magnetic resonance imaging.
    Gratz S, Kemke B, Kaiser W, Heinis J, Behr TM, Höffken H.
    J Int Med Res; 2010; 38(2):633-44. PubMed ID: 20515577
    [Abstract] [Full Text] [Related]

  • 2. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T, Kuwabara M, Yagyu Y, Kumano S, Imaoka I, Tsuchiya N, Ashikaga R, Hosono M, Murakami T.
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [Abstract] [Full Text] [Related]

  • 3. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
    Perri M, Erba P, Volterrani D, Guidoccio F, Lazzeri E, Caramella D, Mariani G.
    AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
    [Abstract] [Full Text] [Related]

  • 4. FDG-PET and CT characterization of adrenal lesions in cancer patients.
    Jana S, Zhang T, Milstein DM, Isasi CR, Blaufox MD.
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):29-35. PubMed ID: 16193311
    [Abstract] [Full Text] [Related]

  • 5. Does 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?
    Tessonnier L, Sebag F, Palazzo FF, Colavolpe C, De Micco C, Mancini J, Conte-Devolx B, Henry JF, Mundler O, Taïeb D.
    Eur J Nucl Med Mol Imaging; 2008 Nov; 35(11):2018-25. PubMed ID: 18566816
    [Abstract] [Full Text] [Related]

  • 6. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI, Cheon GJ, Paeng JC, Cho JY, Kang KW, Chung JK, Kim EE, Lee DS.
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [Abstract] [Full Text] [Related]

  • 7. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P, Kara T, Kara Gedik G, Kara F, Sahin O, Ceylan Gunay E, Sari O.
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [Abstract] [Full Text] [Related]

  • 8. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
    Koopman D, van Dalen JA, Stigt JA, Slump CH, Knollema S, Jager PL.
    Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
    [Abstract] [Full Text] [Related]

  • 9. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
    Brady MJ, Thomas J, Wong TZ, Franklin KM, Ho LM, Paulson EK.
    Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319
    [Abstract] [Full Text] [Related]

  • 10. 18F-FDG-PET/CT Evaluation of Indeterminate Adrenal Masses in Noncancer Patients.
    He X, Caoili EM, Avram AM, Miller BS, Else T.
    J Clin Endocrinol Metab; 2021 Apr 23; 106(5):1448-1459. PubMed ID: 33524123
    [Abstract] [Full Text] [Related]

  • 11. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
    Boland GW, Blake MA, Holalkere NS, Hahn PF.
    AJR Am J Roentgenol; 2009 Apr 23; 192(4):956-62. PubMed ID: 19304700
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic performance of unenhanced computed tomography and 18 F-fluorodeoxyglucose positron emission tomography in indeterminate adrenal tumours.
    Delivanis DA, Bancos I, Atwell TD, Schmit GD, Eiken PW, Natt N, Erickson D, Maraka S, Young WF, Nathan MA.
    Clin Endocrinol (Oxf); 2018 Jan 23; 88(1):30-36. PubMed ID: 28815667
    [Abstract] [Full Text] [Related]

  • 13. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
    Cho WI, Chang UK.
    J Neurosurg Spine; 2011 Feb 23; 14(2):177-83. PubMed ID: 21214309
    [Abstract] [Full Text] [Related]

  • 14. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
    Chae EY, Cha JH, Kim HH, Shin HJ, Kim HJ, Oh HY, Koh YH, Moon DH.
    Acta Radiol; 2012 Jun 01; 53(5):530-5. PubMed ID: 22593124
    [Abstract] [Full Text] [Related]

  • 15. 18F-FDG PET/CT in the evaluation of adrenal masses.
    Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E.
    J Nucl Med; 2006 Jan 01; 47(1):32-7. PubMed ID: 16391184
    [Abstract] [Full Text] [Related]

  • 16. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X, Wu P, Sun X, Li W, Wan H, Yu J, Xing L.
    J Med Imaging Radiat Oncol; 2015 Jun 01; 59(3):338-45. PubMed ID: 25708154
    [Abstract] [Full Text] [Related]

  • 17. Characterization of the normal adrenal gland with 18F-FDG PET/CT.
    Bagheri B, Maurer AH, Cone L, Doss M, Adler L.
    J Nucl Med; 2004 Aug 01; 45(8):1340-3. PubMed ID: 15299059
    [Abstract] [Full Text] [Related]

  • 18. Standardized uptake value-based evaluations of solitary pulmonary nodules using F-18 fluorodeoxyglucose-PET/computed tomography.
    Degirmenci B, Wilson D, Laymon CM, Becker C, Mason NS, Bencherif B, Agarwal A, Luketich J, Landreneau R, Avril N.
    Nucl Med Commun; 2008 Jul 01; 29(7):614-22. PubMed ID: 18528183
    [Abstract] [Full Text] [Related]

  • 19. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?
    Schaarschmidt BM, Grueneisen J, Heusch P, Gomez B, Umutlu L, Ruhlmann V, Rosenbaum-Krumme S, Antoch G, Buchbender C.
    Nucl Med Commun; 2015 Jun 01; 36(6):588-95. PubMed ID: 25759944
    [Abstract] [Full Text] [Related]

  • 20. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS, Shon OJ, Han DS, Choi JH, Chun KA, Cho IH.
    Ann Nucl Med; 2008 Aug 01; 22(7):603-9. PubMed ID: 18756363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.